| Literature DB >> 29370671 |
Jiwoong Jang, Hun-Young Park, Choongsung Yoo, Yeram Park, Jisu Kim, Kiwon Lim.
Abstract
PURPOSE: Resistance exercise training (RET) and an additional intake of dietary protein supplements may improve muscle mass and muscular function, and reduce inflammatory markers. The types, amount, and timing of dietary protein supplements are important for the synergistic effects of resistance training and dietary protein supplements. We hypothesized that a 25.1 g protein complex supplement taken for 12 weeks, immediately before and after resistance exercise, would enhance fat free mass and isokinetic muscular function in young untrained males.Entities:
Keywords: protein supplement
Year: 2017 PMID: 29370671 PMCID: PMC5772071 DOI: 10.20463/jenb.2017.0036
Source DB: PubMed Journal: J Exerc Nutrition Biochem ISSN: 2233-6834
Participant characteristics before training.
| Placebo group | Protein supplement | |
|---|---|---|
| Age(y) | 23.3 ± 3.1 | 24.6 ± 1.8 |
| Weight(kg) | 76.7 ± 10.3 | 70.8 ± 10.7 |
| Height(cm) | 174.6 ± 8.0 | 175.4 ± 7.8 |
| BMI(kg/m2) | 25.1 ± 2.6 | 22.6 ± 2.9 |
| Fat free mass(kg) | 58.9 ± 6.7 | 58.1 ± 6.3 |
| Fat mass(kg) | 17.8 ± 4.8 | 12.7 ± 6.5 |
Note. Data are means ± S.D. BMI = body mass index
The 12-weeks resistance exercise program
| Type | Content | Intensity | Time | |
|---|---|---|---|---|
| Warm- | Stretching | RPE 8 to10 | 10 | |
| Main | Upper | Bench press | 3sets | 45 |
| Barbell rowing | ||||
| Preacher bench biceps curl | ||||
| Dumbbell shoulder press | ||||
| Lower | Barbell squat | |||
| Dead lift | ||||
| Seated leg extension | ||||
| Lying leg curl | ||||
| Cool- | Stretching | RPE 8 to10 | 10 | |
Change in body composition for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | |||||
| Weight | Pla | 76.7 | 76.1 | 75.9 | 77.4 | Ex | 0.209 | 0.089 |
| Pro | 70.8 | 71.2 | 71.2 | 72.3 | ||||
| FFM | Pla | 58.9 | 59.3 | 58.5 | 60.3 | Ex | 0.003 | 0.275 |
| Pro | 58.1 | 59.8 | 58.9 | 60.3 | ||||
| FFM | Pla | 17.8 | 16.8 | 17.5 | 17.1 | Ex | 0.132 | 0.116 |
| Pro | 12.7 | 11.4 | 12.3 | 12.1 | ||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, FFM: fat free mass, FM: fat mass.
††Significant main effect, p <0.01.
Change in blood pressure for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | |||||
| SBP | Pla | 127.0 | 125.6 | 126.2 | 120.3 | Ex | 0.003 | 0.284 |
| Pro | 122.7 | 115.8 | 122.2 | 114.5 | ||||
| DBP | Pla | 75.5 | 67.9 | 68.1 | 65.5 | Ex | 0.000 | 0.598 |
| Pro | 70.8 | 62.2 | 63.1 | 57.4 | ||||
| MAP | Pla | 92.7 | 87.1 | 87.4 | 83.7 | Ex | 0.000 | 0.559 |
| Pro | 88.1 | 80.1 | 82.8 | 76.4 | ||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial pressure.
††Significant main effect, p<0.01.
†††Significant main effect, p<0.001.
Change in blood vessel and muscle inflammation factors for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | |||||
| CRP | Pla | 0.03 | 0.05 | 0.11 | 0.05 | Ex | 0.066 | 0.150 |
| Pro | 0.07 | 0.06 | 0.06 | 0.05 | ||||
| CK | Pla | 176.6 | 127.3 | 166.4 | 223.1 | Ex | 0.024 | 0.208 |
| Pro | 165.1 | 172.4 | 194.8 | 228.7 | ||||
| LDH | Pla | 318.0 | 307.5 | 354.9 | 346.6 | Ex | 0.000 | 0.467 |
| Pro | 296.7 | 297.4 | 333.2 | 341.7 | ||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, CRP: C-reactive protein, CK: creatine kinase, LDH: lactate dehydrogenase
†Significant interaction or main effect, p <0.05.
†††Significant interaction or main effect, p <0.001.
Change in blood lipid level for 12 weeks training in each supplement group
| Variable | Group | Training period (week) | p | η2 | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | |||||
| TC | Pla | 180.5 | 165.5 | 183.8 | 179.0 | Ex | 0.036 | 0.178 |
| Pro | 176.4 | 177.7 | 188.2 | 184.2 | ||||
| LDL | Pla | 108.9 | 91.4 | 104.6 | 100.4 | Ex | 0.135 | 0.113 |
| Pro | 110.2 | 108.6 | 112.4 | 109.6 | ||||
| HDL | Pla | 56.9 | 61.4 | 68.9 | 66.3 | Ex | 0.000 | 0.540 |
| Pro | 52.2 | 52.1 | 62.1 | 64.2 | ||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, TC: total cholesterol, LDL: low density lipoprotein, HDL: high density lipoprotein.
†Significant main effect, p <0.05.
†††Significant main effect, p <0.001.
Change in upper extremity isokinetic muscular function parameters at 60 degrees/sec for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | ||||||
| Ext | Peak torque (Nm) | Pla | 53.8 | 54.8 | 57.8 | 58.8 | Ex | 0.000 | 0.585 |
| Pro | 53.3 | 57.5 | 58.9 | 63.3 | |||||
| Peak torque | Pla | 71.6 | 75.0 | 77.3 | 91.2 | Ex | 0.000 | 0.649 | |
| Pro | 75.8 | 83.6 | 86.1 | 40.1 | |||||
| Flex | Peak | Pla | 34.6 | 39.4 | 38.4 | 40.1 | Ex | 0.000 | 0.661 |
| Pro | 32.0 | 38.0 | 35.9 | 39.3 | |||||
| Peak torque | Pla | 45.8 | 52.0 | 50.9 | 52.0 | Ex | 0.000 | 0.634 | |
| Pro | 46.1 | 54.3 | 51.3 | 55.1 | |||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, Ext = extension, Flex = flexion.
†††Significant main effect, p <0.01.
Change in lower extremity isokinetic muscular function parameters at 240 degrees/sec for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | ||||||
| Ext | Average | Pla | 185.8 | 182.3 | 193.0 | 195.5 | Ex | 0.002 | 0.322 |
| Pro | 176.4 | 190.3 | 186.6 | 205.6 | |||||
| Total work | Pla | 1764.9 | 1770.2 | 1871.2 | 1892.6 | Ex | 0.000 | 0.383 | |
| Pro | 1694.2 | 1891.4 | 1814.5 | 2015.8 | |||||
| Flex | Average | Pla | 83.0 | 79.2 | 88.9 | 95.7 | Ex | 0.000 | 0.550 |
| Pro | 79.1 | 90.1 | 93.7 | 107.4 | |||||
| Total work | Pla | 860.7 | 876.6 | 934.8 | 962.0 | Ex Suppl Ex x Suppl | 0.000 | 0.592 | |
| Pro | 893.9 | 1030.9 | 1084.9 | 1190.0 | |||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, Ext: extension, Flex: flexion.
†Significant interaction effect, p<0.05.
††Significant main effect, p<0.01.
†††Significant main effect. p<0.01.
a p <0.05 versus. Week0, η2p <0.05 versus. Week4, η2p <0.05 versus Week8.
Change in lower extremity isokinetic muscular function parameters at 60 degrees/sec for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | ||||||
| Ext | Peak | Pla | 200.8 | 189.8 | 201.4 | 201.6 | Ex | 0.000 | 0.320 |
| Pro | 201.9 | 200.8 | 202.0 | 214.7 | |||||
| Peak torque | Pla | 264.6 | 253.4 | 267.1 | 265.5 | Ex | 0.031† | 0.178 | |
| Pro | 287.3 | 285.9 | 283.2 | 299.8 | |||||
| Flex | Peak | Pla | 93.0 | 93.7 | 102.2 | 103.0 | Ex | 0.000 | 0.389 |
| Pro | 91.9 | 94.7 | 100.5 | 106.9 | |||||
| Peak torque | Pla | 122.6 | 124.8 | 134.7 | 139.0 | Ex | 0.000 | 0.399 | |
| Pro | 131.3 | 135.7 | 142.7 | 151.6 | |||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, Ext: extension, Flex: flexion.
†Significant interaction or main effect, p <0.05.
††Significant main effect, p <0.01.
†††Significant main effect, p <0.01.
a p <0.05 versus. Week0
b p <0.05 versus. Week4
c p <0.05 versus Week8
Change in upper extremity isokinetic muscular function parameters at 240 degrees/sec for 12 weeks training in each supplement group
| Variable | Group | Training period (week) |
| η2 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | ||||||
| Ext | Average | Pla | 71.6 | 76.2 | 82.1 | 79.9 | Ex | 0.002 | 0.322 |
| Pro | 74.2 | 78.2 | 83.3 | 91.2 | |||||
| Total work | Pla | 1050.5 | 1128.2 | 1176.4 | 1141.2 | Ex | 0.000 | 0.383 | |
| Pro | 1040.4 | 1136.7 | 1170.5 | 1253.0 | |||||
| Flex | Average | Pla | 22.2 | 28.1 | 28.4 | 28.9 | Ex | 0.000 | 0.550 |
| Pro | 21.9 | 27.5 | 28.9 | 30.9 | |||||
| Total work | Pla | 360.3 | 419.6 | 422.7 | 424.6 | Ex | 0.000 | 0.592 | |
| Pro | 339.9 | 414.7 | 433.7 | 449.2 | |||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, Ext: extension, Flex: flexion.
††Significant main effect, p <0.01.
†††Significant main effect, p <0.01.